| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3245 |
| Trial ID | NCT05625594 |
| Disease | Central Nervous System Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma |
| Year | 2022 |
| Country | United States |
| Company sponsor | City of Hope Medical Center |
| Other ID(s) | 22240|NCI-2022-09152|22240|P30CA033572|R01CA266611 |
| Cohort 1 | |||||||||
|
|||||||||